Literature DB >> 21441027

Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.

Bernard Barlaam1, Richard Ducray, Christine Lambert-van der Brempt, Patrick Plé, Catherine Bardelle, Nigel Brooks, Tanya Coleman, Darren Cross, Jason G Kettle, Jon Read.   

Abstract

Optimization of our bis-anilino-pyrimidine series of EphB4 kinase inhibitors led to the discovery of compound 12 which incorporates a key m-hydroxymethylene group on the C4 aniline. 12 displays a good kinase selectivity profile, good physical properties and pharmacokinetic parameters, suggesting it is a suitable candidate to investigate the therapeutic potential of EphB4 kinase inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441027     DOI: 10.1016/j.bmcl.2011.03.009

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

2.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

3.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

Review 4.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

5.  Completing the structural family portrait of the human EphB tyrosine kinase domains.

Authors:  Ross C Overman; Judit E Debreczeni; Caroline M Truman; Mark S McAlister; Teresa K Attwood
Journal:  Protein Sci       Date:  2014-03-11       Impact factor: 6.725

6.  Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

Authors:  William McCoull; Edward J Hennessy; Kevin Blades; Claudio Chuaqui; James E Dowling; Andrew D Ferguson; Frederick W Goldberg; Nicholas Howe; Christopher R Jones; Paul D Kemmitt; Gillian Lamont; Jeffrey G Varnes; Richard A Ward; Bin Yang
Journal:  ACS Med Chem Lett       Date:  2016-09-14       Impact factor: 4.345

7.  Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.

Authors:  Massimiliano Tognolini; Matteo Incerti; Iftiin Hassan-Mohamed; Carmine Giorgio; Simonetta Russo; Renato Bruni; Barbara Lelli; Luisa Bracci; Roberta Noberini; Elena B Pasquale; Elisabetta Barocelli; Paola Vicini; Marco Mor; Alessio Lodola
Journal:  ChemMedChem       Date:  2012-04-23       Impact factor: 3.466

8.  Ligand-Promoted meta-C-H Amination and Alkynylation.

Authors:  Peng Wang; Gen-Cheng Li; Pankaj Jain; Marcus E Farmer; Jian He; Peng-Xiang Shen; Jin-Quan Yu
Journal:  J Am Chem Soc       Date:  2016-10-13       Impact factor: 15.419

9.  Dispensing processes impact apparent biological activity as determined by computational and statistical analyses.

Authors:  Sean Ekins; Joe Olechno; Antony J Williams
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

Review 10.  The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.

Authors:  Enming Du; Xue Li; Siyu He; Xiaohua Li; Shikun He
Journal:  Mol Biol Rep       Date:  2020-06-02       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.